These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 19712766)

  • 1. Monitoring adverse events following yellow fever vaccination using an integrated telephone and Internet-based system.
    Durbin AP; Setse R; Omer SB; Palmer JG; Spaeder JA; Baker J; Lessans F; Halsey NA
    Vaccine; 2009 Oct; 27(44):6143-7. PubMed ID: 19712766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse event reports following yellow fever vaccination.
    Lindsey NP; Schroeder BA; Miller ER; Braun MM; Hinckley AF; Marano N; Slade BA; Barnett ED; Brunette GW; Horan K; Staples JE; Kozarsky PE; Hayes EB
    Vaccine; 2008 Nov; 26(48):6077-82. PubMed ID: 18809449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events.
    Khromava AY; Eidex RB; Weld LH; Kohl KS; Bradshaw RD; Chen RT; Cetron MS;
    Vaccine; 2005 May; 23(25):3256-63. PubMed ID: 15837230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of adverse events reported following use of yellow fever vaccine--Canada, 1987-2000.
    Choudri Y; Walop W
    Can Commun Dis Rep; 2002 Jan; 28(2):9-15. PubMed ID: 11847905
    [No Abstract]   [Full Text] [Related]  

  • 5. Yellow fever vaccination: how much is enough?
    Massad E; Coutinho FA; Burattini MN; Lopez LF; Struchiner CJ
    Vaccine; 2005 Jun; 23(30):3908-14. PubMed ID: 15917112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yellow fever: epidemiology and prevention.
    Barnett ED
    Clin Infect Dis; 2007 Mar; 44(6):850-6. PubMed ID: 17304460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yellow fever vaccination: some thoughts on how much is enough [Vaccine 23 (2005) 3908-3914].
    Martins RM; Galler R; Freire MS; Camacho LA; de Lourdes S Maia M; Homma A
    Vaccine; 2007 Jan; 25(1):10-1. PubMed ID: 16448728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active surveillance for influenza vaccine adverse events: the integrated vaccine surveillance system.
    Newes-Adeyi G; Greece J; Bozeman S; Walker DK; Lewis F; Gidudu J
    Vaccine; 2012 Feb; 30(6):1050-5. PubMed ID: 22200501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Internet-based reporting to the vaccine adverse event reporting system: a more timely and complete way for providers to support vaccine safety.
    Haber P; Iskander J; Walton K; Campbell SR; Kohl KS
    Pediatrics; 2011 May; 127 Suppl 1():S39-44. PubMed ID: 21502243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999-2005.
    Fernandes GC; Camacho LA; Sá Carvalho M; Batista M; de Almeida SM
    Vaccine; 2007 Apr; 25(16):3124-8. PubMed ID: 17316927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and safety of vaccination against yellow fever of persons traveling to endemic areas].
    Dabrowska MM; Flisiak R
    Przegl Epidemiol; 2010; 64(2):319-22. PubMed ID: 20731245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Yellow fever - prevention in travellers.
    Neilson AA; Mayer CA
    Aust Fam Physician; 2010 Aug; 39(8):570-3. PubMed ID: 20877751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Typhoid fever in travelers: who should be targeted for prevention?
    Steinberg EB; Bishop R; Haber P; Dempsey AF; Hoekstra RM; Nelson JM; Ackers M; Calugar A; Mintz ED
    Clin Infect Dis; 2004 Jul; 39(2):186-91. PubMed ID: 15307027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viscerotropic disease following yellow fever vaccination in Peru.
    Whittembury A; Ramirez G; Hernández H; Ropero AM; Waterman S; Ticona M; Brinton M; Uchuya J; Gershman M; Toledo W; Staples E; Campos C; Martínez M; Chang GJ; Cabezas C; Lanciotti R; Zaki S; Montgomery JM; Monath T; Hayes E
    Vaccine; 2009 Oct; 27(43):5974-81. PubMed ID: 19679215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-related risk of adverse events following yellow fever vaccination in Australia.
    Lawrence GL; Burgess MA; Kass RB
    Commun Dis Intell Q Rep; 2004; 28(2):244-8. PubMed ID: 15460963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yellow fever vaccine-associated adverse events following extensive immunization in Argentina.
    Biscayart C; Carrega ME; Sagradini S; Gentile A; Stecher D; Orduna T; Bentancourt S; Jiménez SG; Flynn LP; Arce GP; Uboldi MA; Bugna L; Morales MA; Digilio C; Fabbri C; Enría D; Diosque M; Vizzotti C
    Vaccine; 2014 Mar; 32(11):1266-72. PubMed ID: 24456625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of Typhim Vi vaccine in a postmarketing observational study.
    Marcus LC; Froeschle JE; Hill DR; Wolfe MS; Maus D; Connor B; Acosta AM; Rensimer ER; Roberts A; Dardick K
    J Travel Med; 2007; 14(6):386-91. PubMed ID: 17995534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acceptability of Internet adverse event self-reporting for pandemic and seasonal influenza immunization among health care workers.
    Lapphra K; Dobson S; Bettinger JA
    Vaccine; 2010 Aug; 28(38):6199-202. PubMed ID: 20654668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short report: Incidence of yellow fever vaccine-associated neurotropic disease.
    Guimard T; Minjolle S; Polard E; Fily F; Zeller H; Michelet C; Tattevin P
    Am J Trop Med Hyg; 2009 Dec; 81(6):1141-3. PubMed ID: 19996449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.